Price Alert

Pulmonx Corporation (LUNG)

NASDAQ: LUNG · Real-Time Price · USD

1.71

-0.05 (-2.84%)

At close: Aug 29, 2025, 3:59 PM

1.72

0.52%

After-hours: Aug 29, 2025, 07:16 PM EDT

-2.84% (1D)

Bid	1.62
Market Cap	69.68M
Revenue (ttm)	90.55M
Net Income (ttm)	-56.94M
EPS (ttm)	-1.43
PE Ratio (ttm)	-1.2
Forward PE	-1.29
Analyst	Buy

Ask	1.91
Volume	398,430
Avg. Volume (20D)	626,142
Open	1.76
Previous Close	1.76
Day's Range	1.70 - 1.78
52-Week Range	1.47 - 9.37
Beta	0.43

About LUNG

undefined

[Read more]

Industry n/a

Sector n/a

IPO Date n/a

Employees NaN

Stock Exchange n/a

Ticker Symbol LUNG

Website n/a

Full Company Profile

Analyst Forecast

According to 0 analyst ratings, the average rating for LUNG stock is "n/a." The 12-month stock price forecast is $n/a, which is a decrease of 0% from the latest price.

Stock Forecasts

Next Earnings Release

Pulmonx Corporation is scheduled to release its earnings on Oct 29, 2025, during market hours.
Analysts project revenue of ... Unlock content with Pro Subscription

Why Price Moved

1 month ago

-41.59%

Pulmonx shares are trading lower after the company... Unlock content with Pro Subscription

1 month ago

+1.94%

Pulmonx shares are trading lower after the company reported Q2 financial results and cut its FY25 sales guidance below estimates.

News

6 days ago · zacks.com

What Makes Pulmonx (LUNG) a New Buy Stock

Pulmonx (LUNG) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.

3 weeks ago · zacks.com

After Plunging 37.5% in 4 Weeks, Here's Why the Trend Might Reverse for Pulmonx (LUNG)

Pulmonx (LUNG) is technically in oversold territory now, so the heavy selling pressure might have exhausted. This along with strong agreement among Wall Street analysts in raising earnings estimates c...

1 month ago · seekingalpha.com

Pulmonx Corporation (LUNG) Q2 2025 Earnings Call Transcript

Pulmonx Corporation (NASDAQ:LUNG ) Q2 2025 Earnings Conference Call July 30, 2025 4:30 AM ET Company Participants Mehul Joshi - Chief Financial Officer Steven S. Williamson - CEO, President & Director...

1 month ago · zacks.com

Pulmonx Corporation (LUNG) Reports Q2 Loss, Beats Revenue Estimates

Pulmonx Corporation (LUNG) came out with a quarterly loss of $0.38 per share versus the Zacks Consensus Estimate of a loss of $0.4. This compares to a loss of $0.39 per share a year ago.